SJCARB7H3_41BBL

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameSJCARB7H3_41BBL
Drug Alias NameSJCARB7H3_41BBL
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD276 antigen modulatorsT lymphocyte replacements
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursAdrenocortical CarcinomaCarcinoma +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSt. Jude Children'S Research Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSt. Jude Children'S Research Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursAdrenocortical CarcinomaCarcinoma +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A